• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重度慢性心力衰竭“恶病质”患者体内肿瘤坏死因子浓度升高。

Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure.

作者信息

McMurray J, Abdullah I, Dargie H J, Shapiro D

机构信息

Department of Cardiology, Western Infirmary, Glasgow.

出版信息

Br Heart J. 1991 Nov;66(5):356-8. doi: 10.1136/hrt.66.5.356.

DOI:10.1136/hrt.66.5.356
PMID:1747295
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1024773/
Abstract

OBJECTIVE

To ascertain whether patients with cardiac failure and reduced body weight ("cardiac cachexia") have increased circulating concentrations of tumour necrosis factor (cachectin).

DESIGN

Patients with cardiac failure were prospectively identified as "cachectic" (body fat less than 27% in men and less than 29% in women measured by skinfold thickness callipers) or "non-cachectic". Tumour necrosis factor was assayed blind to patient group.

SETTING

Cardiology unit in a tertiary referral centre.

PATIENTS

26 consecutive patients (10 women) (mean age 61) admitted for investigation or treatment of chronic heart failure. All were in New York Heart Association class III or IV.

RESULTS

In nine of the 16 cachectic patients the concentration of tumour necrosis factor was increased (mean (SEM) 74 (20) pg/ml) compared with one of the 10 "non-cachectic" patients (22 pg/ml, p less than 0.001). Patients with a raised circulating concentration of tumour necrosis factor weighed significantly less (55.6 (3.5) kg) than those in whom the concentration of tumour necrosis factor was normal (69.0 (4.1) kg) (p = 0.02).

CONCLUSIONS

Circulating concentrations of tumour necrosis factor were increased in a significant proportion of patients with chronic heart failure and low body weight. Tumour necrosis factor stimulates catabolism experimentally and it may be a factor in the weight loss seen in patients with "cardiac cachexia".

摘要

目的

确定心力衰竭且体重减轻(“心源性恶病质”)的患者循环中肿瘤坏死因子(恶病质素)浓度是否升高。

设计

前瞻性地将心力衰竭患者分为“恶病质组”(通过皮褶厚度卡尺测量,男性体脂低于27%,女性低于29%)或“非恶病质组”。对患者分组情况进行盲法检测肿瘤坏死因子。

地点

一家三级转诊中心的心脏病科。

患者

26例连续入院接受慢性心力衰竭检查或治疗的患者(10名女性)(平均年龄61岁)。所有患者均为纽约心脏协会心功能Ⅲ级或Ⅳ级。

结果

16例恶病质患者中有9例肿瘤坏死因子浓度升高(平均(标准误)74(20)pg/ml),而10例“非恶病质”患者中仅有1例升高(22 pg/ml,p<0.001)。循环中肿瘤坏死因子浓度升高的患者体重(55.6(3.5)kg)明显低于肿瘤坏死因子浓度正常的患者(69.0(4.1)kg)(p = 0.02)。

结论

相当一部分慢性心力衰竭且体重低的患者循环中肿瘤坏死因子浓度升高。肿瘤坏死因子在实验中可刺激分解代谢,可能是“心源性恶病质”患者体重减轻的一个因素。

相似文献

1
Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure.重度慢性心力衰竭“恶病质”患者体内肿瘤坏死因子浓度升高。
Br Heart J. 1991 Nov;66(5):356-8. doi: 10.1136/hrt.66.5.356.
2
Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure.与慢性心力衰竭相关的恶病质中血浆瘦素浓度异常降低。
Heart. 1999 Sep;82(3):352-6. doi: 10.1136/hrt.82.3.352.
3
Tumor necrosis factor-alpha serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure.晚期充血性心力衰竭恶病质和非恶病质患者急性失代偿期治疗期间的肿瘤坏死因子-α血清活性
Scand Cardiovasc J. 1999;33(6):344-50. doi: 10.1080/14017439950141407.
4
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.
N Engl J Med. 1990 Jul 26;323(4):236-41. doi: 10.1056/NEJM199007263230405.
5
Adropin and Irisin in Patients with Cardiac Cachexia.心脏恶病质患者体内的内脂素和鸢尾素
Arq Bras Cardiol. 2018 Jul;111(1):39-47. doi: 10.5935/abc.20180109. Epub 2018 Jul 2.
6
Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia.恶病质慢性心力衰竭患者血浆肿瘤坏死因子水平升高。
Int J Cardiol. 1997 Feb;58(3):257-61. doi: 10.1016/s0167-5273(96)02873-2.
7
Adiponectin is increased in cardiac cachexia irrespective of body mass index.无论体重指数如何,心脏恶病质患者体内的脂联素水平都会升高。
Eur J Heart Fail. 2009 Jun;11(6):567-72. doi: 10.1093/eurjhf/hfp046. Epub 2009 Apr 9.
8
Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure.慢性心力衰竭患者全血中内毒素诱导的肿瘤坏死因子-α释放的病理生理量。
Am J Cardiol. 2002 Dec 1;90(11):1226-30. doi: 10.1016/s0002-9149(02)02839-4.
9
Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.消瘦型心力衰竭患者心脏与脂肪组织间的串扰及其与机体成分改变的关系:一项前瞻性研究。
Metabolism. 2014 Jan;63(1):141-9. doi: 10.1016/j.metabol.2013.09.017. Epub 2013 Oct 17.
10
Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure.慢性心力衰竭恶病质和非恶病质患者外周血单个核细胞中的核因子-κB活性
Int J Cardiol. 2007 Nov 15;122(2):111-6. doi: 10.1016/j.ijcard.2006.03.095. Epub 2007 Jan 30.

引用本文的文献

1
Integrated multi-omics approach revealed TTNtv c.13254T>G causing dilated cardiomyopathy in mice.整合多组学方法揭示 TTNtv c.13254T>G 导致小鼠扩张型心肌病。
PLoS One. 2024 Oct 4;19(10):e0311670. doi: 10.1371/journal.pone.0311670. eCollection 2024.
2
Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI?正常体重、超重和肥胖的扩张型非缺血性心肌病患者的肿瘤坏死因子-α及可溶性肿瘤坏死因子受体水平:根据体重指数,抗肿瘤坏死因子治疗在心力衰竭中仍有应用潜力吗?
Biomedicines. 2022 Nov 17;10(11):2959. doi: 10.3390/biomedicines10112959.
3
The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases.非酒精性脂肪性肝病与心血管疾病之间的遗传相互作用。
Front Genet. 2022 Aug 10;13:971484. doi: 10.3389/fgene.2022.971484. eCollection 2022.
4
Frailty assessment using a novel approach based on combined motor and cardiac functions: a pilot study.基于运动和心脏功能联合的新型衰弱评估方法:一项初步研究。
BMC Geriatr. 2022 Mar 14;22(1):199. doi: 10.1186/s12877-022-02849-3.
5
The association between heart rate behavior and gait performance: The moderating effect of frailty.心率行为与步态表现之间的关联:衰弱的调节作用。
PLoS One. 2022 Feb 16;17(2):e0264013. doi: 10.1371/journal.pone.0264013. eCollection 2022.
6
Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.心房颤动和心力衰竭患者临床管理中的生物标志物
J Geriatr Cardiol. 2021 Nov 28;18(11):908-951. doi: 10.11909/j.issn.1671-5411.2021.11.010.
7
Measuring ketone bodies for the monitoring of pathologic and therapeutic ketosis.测量酮体以监测病理性和治疗性酮症。
Obes Sci Pract. 2021 May 4;7(5):646-656. doi: 10.1002/osp4.516. eCollection 2021 Oct.
8
JNK and NF-κB signaling pathways are involved in cytokine changes in patients with congenital heart disease prior to and after transcatheter closure.JNK和NF-κB信号通路参与先天性心脏病患者经导管封堵术前和术后的细胞因子变化。
Exp Ther Med. 2018 Feb;15(2):1525-1531. doi: 10.3892/etm.2017.5595. Epub 2017 Dec 5.
9
Sudden cardiac death in patients with rheumatoid arthritis.类风湿关节炎患者的心脏性猝死
World J Cardiol. 2017 Jul 26;9(7):562-573. doi: 10.4330/wjc.v9.i7.562.
10
sTNF-R Levels: Apical Periodontitis Linked to Coronary Heart Disease.可溶性肿瘤坏死因子受体水平:根尖周炎与冠心病的关联
Open Access Maced J Med Sci. 2017 Mar 15;5(1):68-71. doi: 10.3889/oamjms.2017.010. Epub 2017 Jan 17.

本文引用的文献

1
Nutritional assessment as a routine in clinical medicine.
Postgrad Med. 1982 May;71(5):46-63. doi: 10.1080/00325481.1982.11716062.
2
Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years.通过总体密度评估身体脂肪及其从皮褶厚度进行的估算:对481名年龄在16至72岁之间的男性和女性的测量。
Br J Nutr. 1974 Jul;32(1):77-97. doi: 10.1079/bjn19740060.
3
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.针对恶病质素/肿瘤坏死因子的被动免疫可保护小鼠免受内毒素的致死作用。
Science. 1985 Aug 30;229(4716):869-71. doi: 10.1126/science.3895437.
4
Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential.恶病质素/肿瘤坏死因子介导骨骼肌质膜电位的变化。
J Exp Med. 1986 Oct 1;164(4):1368-73. doi: 10.1084/jem.164.4.1368.
5
Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome.获得性免疫缺陷综合征患者循环中恶病质素/肿瘤坏死因子水平升高。
Am J Med. 1988 Sep;85(3):289-91. doi: 10.1016/0002-9343(88)90576-1.
6
Syndromes of cardiac cachexia and the cachectic heart: current perspective.
Prog Cardiovasc Dis. 1987 Jul-Aug;30(1):45-60. doi: 10.1016/0033-0620(87)90010-7.
7
Influence of blood-collecting systems on concentrations of tumor necrosis factor in serum and plasma.
Clin Chem. 1988 Nov;34(11):2373-4.
8
Tumor necrosis factor and the acute metabolic response to tissue injury in man.肿瘤坏死因子与人体组织损伤的急性代谢反应
J Clin Invest. 1988 Oct;82(4):1321-5. doi: 10.1172/JCI113733.
9
Cachectin and tumour necrosis factor as two sides of the same biological coin.恶病质素与肿瘤坏死因子是同一枚生物硬币的两面。
Nature. 1986;320(6063):584-8. doi: 10.1038/320584a0.
10
Evidence for tumour necrosis factor/cachectin production in cancer.癌症中肿瘤坏死因子/恶病质素产生的证据。
Lancet. 1987 Nov 28;2(8570):1229-32. doi: 10.1016/s0140-6736(87)91850-2.